BIO.B Earnings Prediction
The chart below shows how BIO.B performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BIO.B sees a +14.61% change in stock price 10 days leading up to the earnings, and a +0.00% change 10 days following the report. On the earnings day itself, the stock moves by -2.29%. This data can give you a slight idea of what to expect for the next quarter's release.
BIO.B Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
649.73M
2.79%
1.76%
Gross Margin
54.78%
3.09%
-1.67%
Operating Margin
14.46%
-1.16%
-7.78%
Net Margin
100.53%
498.04%
-129.64%
EPS
23.34
541.21%
-130.61%
No Data Available
BIO.B Earnings Analysis
Bio-Rad Laboratories, Inc. Class B Corporation (BIO.B.N) Earnings Conference Call
Positive
Net Sales Increase: Net sales were $650 million, which represents a 2.8% increase on a reported basis versus $632 million in Q3 2023.
Clinical Diagnostics Sales Growth: On a currency-neutral basis this represents a 3.4% year-over-year increase and was driven primarily by higher sales in our Clinical Diagnostics segment.
Gross Margin Improvement: Q3 reported GAAP gross margin was 54.8% as compared to 53.1% in the third quarter of 2023.
Gross Margin Improvement Factors: The increase in gross margin was primarily driven by improved productivity, lower logistics costs and a mix of revenue.
Free Cash Flow Increase: Third quarter 2024 free cash flow was approximately $123 million which compares to $54 million in Q3 of 2023.
Negative
Net Sales Increase: Net sales were $650 million, which represents a 2.8% increase on a reported basis versus $632 million in Q3 2023.
Life Science Sales Stability: Sales of the Life Science group were approximately $261 million compared to $263 million in Q3 of 2023, which is essentially flat on a reported and currency-neutral basis.
Sales Performance by Region: Currency neutral sales decreased in the Americas offset by the increase in EMEA.
Operating Income Comparison: Q3 operating income is approximately $64 million or 9.9% of sales compared to $91 million or 14.4% of sales in Q3, 2023.
Operating Income Decline: Lower operating income is driven by the one-time in-process R&D expense, which decreased operating income by approximately $30 million.
BIO.B FAQs
How does BIO.B typically perform around its earnings report dates?
How can historical earnings data help predict future stock performance?
BIO.B Earning Call Sentiment
Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BIO.B.N
0.87%Positive
The earnings call presents mixed signals. Financial performance shows a slight increase in net sales and gross margin, but operating income has declined due to a one-time R&D expense. The share repurchase program is a positive, but the revised revenue outlook, especially the decline in Life Science Group revenue, is concerning. The Q&A highlights ongoing destocking and regulatory challenges, with cautious guidance for Q4. The overall sentiment is balanced, resulting in a neutral prediction for stock price movement over the next two weeks.
